# To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

> **NCT05997602** · PHASE2 · RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 56 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis
- LCH

## Interventions

- **DRUG:** FCN-159

## Key facts

- **NCT ID:** NCT05997602
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-28
- **Primary completion:** 2025-05-14
- **Final completion:** 2027-05-14
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05997602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05997602, "To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05997602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*